Hurwitz Amy M, Huang Wanzhi, Kou Baijun, Estes Mary K, Atmar Robert L, Palzkill Timothy
Interdepartmental Program in Translational Biology & Molecular Medicine, Baylor College of Medicine, Houston, Texas, United States of America.
Department of Pharmacology, Baylor College of Medicine, Houston, Texas, United States of America.
PLoS One. 2017 Jan 17;12(1):e0170162. doi: 10.1371/journal.pone.0170162. eCollection 2017.
Norovirus infections commonly lead to outbreaks of acute gastroenteritis and spread quickly, resulting in many health and economic challenges prior to diagnosis. Rapid and reliable diagnostic tests are therefore essential to identify infections and to guide the appropriate clinical responses at the point-of-care. Existing tools, including RT-PCR and enzyme immunoassays, pose several limitations based on the significant time, equipment and expertise required to elicit results. Immunochromatographic assays available for use at the point-of-care have poor sensitivity and specificity, especially for genogroup I noroviruses, thus requiring confirmation of results with more sensitive testing methods. Therefore, there is a clear need for novel reagents to help achieve quick and reliable results. In this study, we have identified two novel single-chain antibodies (scFvs)-named NJT-R3-A2 and NJT-R3-A3-that effectively detect GI.1 and GI.7 virus-like particles (VLPs) through selection of a phage display library against the P-domain of the GI.1 major capsid protein. The limits of detection by each scFv for GI.1 and GI.7 are 0.1 and 0.2 ng, and 6.25 and 25 ng, respectively. They detect VLPs with strong specificity in multiple diagnostic formats, including ELISAs and membrane-based dot blots, and in the context of norovirus-negative stool suspensions. The scFvs also detect native virions effectively in norovirus-positive clinical stool samples. Purified scFvs bind to GI.1 and GI.7 VLPs with equilibrium constant (KD) values of 27 nM and 49 nM, respectively. Overall, the phage-based scFv reagents identified and characterized here show utility for detecting GI.1 and GI.7 noroviruses in multiple diagnostic assay formats with strong specificity and sensitivity, indicating promise for integration into existing point-of-care tests to improve future diagnostics.
诺如病毒感染通常会引发急性肠胃炎疫情,且传播迅速,在诊断之前会带来诸多健康和经济挑战。因此,快速可靠的诊断测试对于识别感染情况并在即时护理点指导适当的临床应对措施至关重要。现有的检测工具,包括逆转录聚合酶链反应(RT-PCR)和酶免疫测定法,由于得出结果需要大量时间、设备和专业知识,存在若干局限性。可在即时护理点使用的免疫层析测定法灵敏度和特异性较差,尤其是对于I基因组诺如病毒,因此需要用更灵敏的检测方法来确认结果。所以,显然需要新型试剂来帮助实现快速可靠的结果。在本研究中,我们鉴定出两种新型单链抗体(scFv)——命名为NJT-R3-A2和NJT-R3-A3——通过针对GI.1主要衣壳蛋白的P结构域筛选噬菌体展示文库,它们能有效检测GI.1和GI.7病毒样颗粒(VLP)。每种scFv对GI.1和GI.7的检测限分别为0.1和0.2纳克,以及6.25和25纳克。它们在多种诊断形式中,包括酶联免疫吸附测定(ELISA)和基于膜的斑点印迹法,以及在诺如病毒阴性粪便悬液的背景下,都能以很强的特异性检测VLP。这些scFv在诺如病毒阳性临床粪便样本中也能有效检测天然病毒粒子。纯化后的scFv分别以27纳摩尔和49纳摩尔的平衡常数(KD)值与GI.1和GI.7 VLP结合。总体而言,此处鉴定和表征的基于噬菌体的scFv试剂在多种诊断测定形式中对检测GI.1和GI.7诺如病毒具有实用性,具有很强的特异性和灵敏度,表明有望整合到现有的即时护理点检测中以改进未来的诊断。